Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Xetra  >  Vita 34 International AG    V3V   DE000A0BL849

Delayed Quote. Delayed  - 08/29 11:40:24 am
4.2 EUR   +1.35%
08/26 VITA 34 INTERNA : ex-dividend day for annual dividend
08/25 VITA 34 AG : Dividend Increased by 7 Percent
08/23 VITA 34 INTERNA : Increases Revenue by 25 Percent in First Half-Year..
News SummaryMost relevantAll newsSector news 

Vita 34 International AG : Vita 34 AG pursues growth strategy by taking over the majority stake in Stellacure

share with twitter share with LinkedIn share with facebook
share via e-mail
01/07/2014 | 05:53pm CEST

Vita 34 AG pursues growth strategy by taking over the majority stake in Stellacure

- Vita 34 takes over 75.24 percent of the shares in Stellacure GmbH

- Further strengthening of market leadership in German-speaking area by take-over

- Future growth potential by establishing a second location in Germany

Leipzig, 7 January 2014 - Vita 34 AG (WKN A0BL84), trailblazer of the umbilical cord blood storage in Europe and specialist in cryo-preservation, takes over the majority stake in the umbilical cord blood bank Stellacure GmbH. Through the application, which was already made, and the registration in the Commercial Registry, which is expected in January 2014, Vita 34 will take over 75.24 percent of the Stellacure shares. Both parties agreed not to disclose the sales price. With this take-over, Vita 34 acquires an established brand in the sector of Vita 34 private umbilical cord blood banking and thus pursues the aspect of the growth strategy of further expanding its own share in the German market.

The Stellacure GmbH was founded in Hamburg and Frankfurt in 2006 in cooperation with the Blood Transfusion Service Baden-Württemberg-Hesse of the German Red Cross (DRK). The operating activities of the Stellacure GmbH include the extraction and processing of umbilical cord blood allowing for the highest quality and safety standards. The cord blood is stored at Stellacure's facility located in the building of the DRK Blood Transfusion Service in Frankfurt on the Main. In addition to storages from Germany, Stellacure furthermore works on the Italian and Spanish markets. The team comprises specialists in transfusion and laboratory medicine as well as experienced experts such as biologists, chemists, biotechnologists, and engineers. Being the fourth eldest provider of umbilical cord blood storage services in Germany, Stellacure produced a turnover of about 0.4 million Euros in the fiscal year 2012.

Dr. André Gerth, CEO of Vita 34 AG: 'We are the market leader in the entire German-speaking area with more than 98,000 stored stem cell preparations. Our ambition is to strengthen this dominant position in a sustainable way. We currently see a growing tendency to consolidation on the market of private umbilical cord blood banking. This process provides us as the market leader with considerable opportunities to gain additional market shares. By taking over the majority of Stellacure, we now have a second location in Germany besides Leipzig, based on which we are able to establish a purposeful regional distribution and thus intensify the contact with our relevant target group.'

Company profile
Vita 34 was founded in 1997 as the first private umbilical cord blood bank in Europe and as a full-service provider takes care of the collection logistics, processing, and storage of umbilical cord blood and umbilical cord tissue. Its successful operation is based on an excellent position in the technological segment of cryo-preservation. Cells and tissue are kept alive at temperatures around minus 190 degrees Celsius and can be applied in medical therapies if required. Parents of more than 98,000 children already make use of this offer and have taken provisions for their children by means of a stem cell depot at the company from Leipzig.

07.01.2014 Dissemination of a Corporate News, transmitted by DGAP - a company of EQS Group AG.

The issuer is solely responsible for the content of this announcement.

DGAP's Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.

distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
08/26 VITA 34 INTERNATIONAL AG : ex-dividend day for annual dividend
08/25 DGAP-DD : Vita 34 AG english
08/25 DGAP-DD : Vita 34 AG deutsch
08/25 VITA 34 AG : Dividend Increased by 7 Percent
08/25 DGAP-NEWS : Vita 34 AG: Dividend Increased by 7 Percent
08/25 DGAP-NEWS : Vita 34 AG: Dividendenausschüttung um 7 Prozent gesteigert
08/23 VITA 34 INTERNATIONAL : Increases Revenue by 25 Percent in First Half-Year 2016
08/23 DGAP-NEWS : Vita 34 steigert Umsatz im 1. Halbjahr 2016 um 25 Prozent
08/23 DGAP-NEWS : Vita 34 Increases Revenue by 25 Percent in First Half-Year 2016
08/16 DGAP-AFR : Vita 34 AG: Vorabbekanntmachung über die Veröffentlichung von Finanzb..
More news
Sector news : Healthcare Facilities & Services - NEC
08/25DJLABORATORY OF AMERICA : Zika's Spread Pushes Testing Labs to Expand Capacity
08/25DJIHH HEALTHCARE BHD : Malaysia's IHH Healthcare 2Q Net Profit Up 7.9%, Sees Cost ..
08/18DJNestlé Reports Subdued Sales Growth
08/02DJFRESENIUS MEDICAL CARE KGAA : Lifts Profit Outlook After Strong North America Pe..
07/29DJFRESENIUS SE KGAA : 2Q 2016 -- Forecast
More sector news : Healthcare Facilities & Services - NEC
Financials (€)
Sales 2016 15,0 M
EBIT 2016 -
Net income 2016 -
Debt 2016 1,00 M
Yield 2016 3,81%
P/E ratio 2016 35,00
P/E ratio 2017 15,00
Capi. / Sales 2016 0,91x
Capi. / Sales 2017 0,85x
Capitalization 12,7 M
More Financials
Duration : Period :
Vita 34 International AG Technical Analysis Chart | V3V | DE000A0BL849 | 4-Traders
Full-screen chart
Technical analysis trends VITA 34 INTERNATI...
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 1
Average target price 7,50 €
Spread / Average Target 79%
Consensus details
EPS Revisions
More Estimates Revisions
André Gerth Chief Executive Officer & IR Contact
Hans-Georg Giering Chairman-Supervisory Board
Falk Neukirch Chief Financial Officer & IR Contact
Holger Födisch Member-Supervisory Board
Alexander Starke Vice Chairman-Supervisory Board
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
HCA HOLDINGS INC10.84%28 383
LABORATORY CORP. OF AM..11.40%14 091
More Results